At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 61 enrolled
Drug / intervention
Risedronate +1 moredrug
Likely dose
Risedronate 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 1-year, Risedronate-free, Multicenter, Outpatient, Phase IIIb Extension Study to Assess Bone Turnover Recovery in Women With Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, and RVE1998080 (no NCT Study Numbers)
In Brief
A Phase 3 clinical trial evaluating Risedronate and Placebo/Risedronate for Postmenopausal Women With Osteoporosis. Completed, enrolled 61 participants across 13 sites in 8 countries.
Detailed Summary
The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Women With Osteoporosis
CountriesAustralia, Belgium, Denmark, Finland, Italy, Poland, Spain, Sweden
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2001
Primary CompletionMay 2003
First PostedNov 2010
TodayJul 2026
First PostedNov 29, 2010
Enrollment StartOct 1, 2001
Primary CompletionMay 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.6 years ago
Interventions
Risedronatedrug
5 mg/day
Placebo/Risedronatedrug
placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8